Report, I've been following this stock for 2 years. Early during covid I was long in it. It was after I concluded that this CEO is obsessed with shrooms that I got out at near B/E (with a slight loss). He had no sense of urgency with the covid phase 3 trial. It became obvious when 90% of the PRs were about "shrooms", and not about phase 3 progress. Once the trial is complete, one can easily add 6-9 months for him to collect the data, analyze, submit EUA, and WAIT for FDA to review it an approval. No sense of urgency with this CEO. When if the pps dips under .05, I may get back in.
Market Data 
Markets 
AI
